UK has bought 30m doses of product that could transform world’s immunisation programmes
A fifth vaccine, made by the US company Johnson & Johnson, has shown efficacy against the coronavirus, giving complete protection against hospitalisation and death, and could transform prospects for protecting both the UK and the rest of the world, because it needs only a single dose.
The vaccine, made by the US giant’s subsidiary Janssen, based in Belgium, was trialled with 44,000 people in the US, South Africa and Brazil. The US has ordered 100m doses with an option for more. Further trials involving a second dose are taking place in the UK – and the British government has bought 30m doses. The EU has ordered 400m doses. The company could not say what the timetable for supply would be, assuming regulators approve it.